You are currently viewing Role of statins in slowing Rheumatic Heart Disease (RHD) progression: A feasibility study for a Randomized Controlled Trial

Role of statins in slowing Rheumatic Heart Disease (RHD) progression: A feasibility study for a Randomized Controlled Trial

Project Summary

Rheumatic Heart Disease (RHD) is a sequela of Acute Rheumatic Fever (ARF) caused by Group A Streptococcus (GAS). Cardiac involvement shows evidence of inflammation, leading to permanent damage of heart valves, primarily the mitral valve. Since the pathogenesis of RHD is linked to autoimmune inflammatory response to GAS, therapeutic strategies that aim to modulate inflammatory response might delay the progression of RHD. Despite compelling biologic and observational data, to date there has not been a Randomized Controlled Trial (RCT) to test whether statins delay the progression of cardiac sequelae and improve clinical outcomes in patients with RHD.

Study Duration

Started from February 08, 2022

Objectives

General Objective
To determine the Role of statins in slowing Rheumatic Heart Disease (RHD) Progression: A feasibility study for a Randomized Controlled Trial

Specific Objective
To determine the rate at which the statin lowers the progression of RHD
To examine the enrollment, adherence, and retention rates for statin
To examine the feasibility of larger RCT from outcomes of the current RCT in this population (specifically, rate of progression of valvular damage)

Team Members

Principal Investigator(s): Dr. Bhagwan Koirala

Co-Investigator(s): Prof. Dr. Rajendra Prasad Koju, Dr. Biraj Man Karmacharya, Assist. Prof. Sanjaya Humagain, Dr. Abha Shrestha, Assist. Prof. Robin Man Karmacharya, Assist. Prof. Chandramani Poudel, Dr. Puspanjali Adhikari, Dr. Archana Shrestha

Project Coordinator: Ms. Anisha Rai

Research Assistants: Ms. Namita Dahal

Collaborating Partners: University of Washington, Dhulikhel Hospital, Manmohan Cardiothoracic Vascular and Transplant Center